AtriCure (NASDAQ:ATRC) Insider Sells 5,166 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Justin Noznesky sold 5,166 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total value of $192,640.14. Following the completion of the transaction, the insider directly owned 78,798 shares in the company, valued at $2,938,377.42. This represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

AtriCure Stock Performance

Shares of ATRC traded down $2.45 during mid-day trading on Wednesday, reaching $36.03. The company had a trading volume of 677,169 shares, compared to its average volume of 552,172. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $1.79 billion, a P/E ratio of -59.06 and a beta of 1.56. The stock has a 50 day moving average of $35.12 and a two-hundred day moving average of $34.21. AtriCure, Inc. has a 52-week low of $28.29 and a 52-week high of $43.11.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.10. The business had revenue of $134.27 million during the quarter, compared to the consensus estimate of $131.25 million. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The business’s quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Institutional Trading of AtriCure

A number of large investors have recently modified their holdings of ATRC. Ameritas Investment Partners Inc. grew its position in AtriCure by 6.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock worth $162,000 after purchasing an additional 312 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in AtriCure by 6.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock worth $218,000 after buying an additional 380 shares in the last quarter. Teacher Retirement System of Texas increased its position in AtriCure by 5.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock valued at $246,000 after acquiring an additional 385 shares during the period. Scotia Capital Inc. boosted its position in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after acquiring an additional 457 shares during the period. Finally, Aster Capital Management DIFC Ltd grew its stake in shares of AtriCure by 197.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after purchasing an additional 538 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analyst Weigh In

ATRC has been the topic of a number of recent analyst reports. Canaccord Genuity Group upped their target price on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. BTIG Research set a $54.00 target price on shares of AtriCure in a research report on Wednesday, July 30th. Needham & Company LLC raised their target price on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and an average price target of $52.22.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.